Based on these finding, PDE9A inhibitors have been advanced into initial clinical studies to assess the potential to improve cognitive function in patients with Alzheimer’s disease and schizophrenia (Schwam et al., 2014; Wunderlich et al., 2016; Boland et al., 2017). Here, PDE9A is linked to schizophrenia.